Glow Peptide: What Is in the Blend, What the Research Shows, and What It Does Not

Research use only. Peptides supplied by Peptryn are sold strictly for in vitro and preclinical laboratory research. They are not approved by the FDA for human or veterinary use, and nothing here is medical advice, a dosing recommendation, or an instruction for self-administration. This guide explains what the Glow peptide blend is, what published research does and does not show, and how researchers should evaluate a vial.

Quick answer: what is Glow peptide?

Glow peptide (also called the Glow blend, the Glow peptide stack, the Glow stack peptide, or just “Glow”) is a research blend of three synthetic peptides: GHK-Cu, BPC-157 and TB-500. In the common 70 mg vial the amounts are GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg. The name points at skin, but the blend is marketed for skin, recovery and general “repair.”

The evidence in one paragraph: each of the three peptides has been studied in cells or animals. GHK-Cu also has small human studies of topical skin products, and full-length thymosin beta-4 (the form behind the name “TB-500” on some listings) has been tested in pharmaceutical-grade products in humans. We found no registered or published human trial of the three together, and none of the three is an FDA-approved drug for these uses. Claims about Glow “benefits” are hypotheses drawn from lab work, not established results.

At a glance

Sourcing for research: Glow blend · Glow COA · Batch COA library · Lab results

---

Table of contents

1. What “Glow peptide” means
2. What is in a Glow blend peptide vial
3. The three peptides in Glow
4. Why these three? The Glow peptide stack logic
5. What the research shows
6. Glow peptide benefits and “before and after” claims
7. Glow vs Klow vs Wolverine vs single peptides
8. Glow peptide dosage: why there is no established one
9. Reconstitution and handling of Glow in the lab
10. Glow peptide side effects and safety
11. Regulatory and sport status
12. Glow peptide reviews and Reddit: how to read anecdotes
13. How to evaluate a Glow vial before you buy
14. Frequently asked questions
15. Final take

---

What “Glow peptide” means

There is no official definition of “Glow.” It is a market name, and no standards body controls it. Across the clinic pages, vendor product pages and explainers we read for this guide, the usual meaning is the same: a fixed-ratio blend of GHK-Cu, BPC-157 and TB-500, most often described as a 70 mg vial. That matches the Peptryn listing.

Three details matter for anyone comparing products:

• The three peptides agree, the details do not. The 50 / 10 / 10 mg split appears on at least one other page besides Peptryn’s, but nothing forces a seller to use it. Two vials sold as “Glow” can differ in amounts.
• “TB-500” is not one molecule. It can mean a 7-amino-acid fragment or full-length thymosin beta-4 (43 amino acids). The Peptryn Glow listing says thymosin beta-4 acetate, the full-length form, while at least one clinic page we read calls it a fragment. This matters for the evidence, and we come back to it below.
• Some pages mean something else. At least one guide we reviewed defined “GLOW” as GHK-Cu with glutathione and ascorbic acid. The certificate of analysis, not the name, tells you what is in a vial.

Some clinics offer Glow as a service under individual clinical judgment. This guide is not about that. It is about what the published evidence says and how to evaluate a research-grade vial.

What is in a Glow blend peptide vial

Amounts come from the Peptryn listing. Two facts are easy to miss:

1. GHK-Cu is most of the vial, and even more of the molecules. It is 71% of the mass, but because it is far smaller than the other two, it makes up roughly 93% of the individual molecules (an arithmetic estimate using the label amounts and the molecular weights above). The 5:1:1 mass ratio also means you cannot change one component without changing the others.
2. “70 mg” is total peptide, not 70 mg of any one compound. Reading it as 70 mg of active material is a misreading of the label.

The three peptides in Glow

GHK-Cu (copper tripeptide)

GHK-Cu is a naturally occurring three-amino-acid peptide (glycyl-L-histidyl-L-lysine) bound to copper. It is found in blood plasma. A 2018 review by Pickart and Margolina reports plasma GHK falling from about 200 ng/mL at age 20 to about 80 ng/mL by age 60, and describes effects on collagen and extracellular-matrix remodeling in laboratory work (Pickart and Margolina, 2018).

The human evidence is topical. The same review describes small studies of creams and serums applied to skin: a 12-week facial cream study in 71 women, a 12-week eye-cream study in 41 women that included placebo and vitamin K cream comparators, a 12-week study comparing GHK-Cu, vitamin C and retinoic acid creams on thigh skin, and an 8-week study of a nano-lipid GHK-Cu formulation against a comparator cream. These are short studies of cosmetic formulations, and we could not independently retrieve each underlying paper. The review also states GHK has been used in cosmetic products for decades without reported adverse effects, which is a statement about skin products and not injections.

Injection is a different question. The FDA lists injectable GHK-Cu on its page of bulk substances that may present significant safety risks for compounding, noting possible immunogenicity from aggregation and peptide-related impurities and limited human data (FDA). The one registered GHK-Cu trial we found in ClinicalTrials.gov is again topical: a Phase 2 study of a 0.1% gel on small skin wounds in healthy adults, still recruiting (NCT07437586).

BPC-157 (Body Protection Compound-157)

BPC-157 is a synthetic 15-amino-acid peptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) described in the 1990s from a protein in human gastric juice. Rodent studies report faster tendon, ligament and muscle healing and effects on blood-vessel growth through VEGFR2 and nitric oxide signaling. A 2025 narrative review counts only three published human reports: a retrospective review of 16 patients with knee pain, a 12-person pilot in interstitial cystitis, and a 2-person intravenous safety pilot. It found no randomized controlled trial and concluded BPC-157 should be treated as investigational (McGuire et al., 2025).

That picture is starting to change. Two randomized, double-blind trials are now registered: a Phase 2 study in acute hamstring strain (120 participants planned, recruiting, NCT07437547) and a small pilot after rotator cuff repair (30 participants, not yet recruiting, NCT07803250). An older oral Phase 1 safety study in healthy volunteers is also registered with its status listed as unknown (NCT02637284). None has posted results. For more on BPC-157 and TB-500, see our Wolverine peptide guide.

TB-500 and thymosin beta-4

Here the name causes real confusion. “TB-500” is used for two different molecules: the 7-amino-acid fragment Ac-LKKTETQ (the 17-23 region), and full-length thymosin beta-4, a 43-amino-acid protein of about 4,963 Da. Peptryn’s Glow listing identifies its TB-500 as thymosin beta-4 acetate, the full-length form, and the standalone TB-500 listing gives 4,963.44 Da. Confirm the form on your COA.

The two have different evidence:

• Full-length thymosin beta-4 has been studied in humans as drug products. ClinicalTrials.gov lists randomized, placebo-controlled trials of topical thymosin beta-4 in venous stasis ulcers (Phase 2, 72 participants, NCT00832091), of RGN-259 eye drops in dry eye (Phase 3, 700 participants, NCT03937882), and of intravenous recombinant thymosin beta-4 in healthy volunteers (Phase 1a, 54 participants, NCT04555824) and in heart attack (Phase 2, 90 participants, NCT05984134). We did not assess whether these trials succeeded. The point is what was tested: pharmaceutical products, given by specific routes under trial conditions, not research vials and not a blend.
• The 7-amino-acid fragment has far less. The FDA states it has identified no human exposure data for it. The first registered human trial we found is a Phase 1/2 safety study in adults with stable cardiovascular disease, started in February 2026 and recruiting, with about 80 participants planned (NCT07487363). It is not a tendon or skin study.

Why these three? The Glow peptide stack logic

The reasoning behind the stack is that each component acts on a different part of tissue repair:

• GHK-Cu: extracellular matrix and collagen turnover
• BPC-157: blood-vessel growth and fibroblast activity in animal injury models
• TB-500 / thymosin beta-4: cell migration and actin dynamics

The logic is intuitive: repair needs new matrix, a blood supply and moving cells. But it is a hypothesis about combining compounds, not a result. We found no published study that tests the three together, even in animals. Combining peptides also adds unknowns: more chances for interactions, impurities, and effects that cannot be attributed to any single component.

What the research shows

This is the honest summary. Every component has laboratory support. GHK-Cu and thymosin beta-4 have controlled human data, but for different products and routes than a research vial. The combination has no direct evidence at all. Evidence status reflects our review as of September 2026 and only sources we could verify.

What the human trials actually tested

Read the table above the way a skeptical researcher would. Each row is a different product, route and population: a topical gel, an eye drop, an oral tablet, a subcutaneous injection given by trial staff, an intravenous drug. None is a lyophilized research blend, and none tests the three peptides together. Registration is also not a result: recruiting trials have no findings yet. The value of this table is that it shows where the real human evidence is being built, and that it is being built one compound and one purpose at a time.

Glow peptide benefits and “before and after” claims

“Glow peptide benefits” and “Glow peptide before and after” are two of the most-searched questions in this topic. The benefits usually claimed online are better skin quality, faster recovery, less inflammation and tissue repair. Here is how to read them:

• They are extrapolations. Each claim traces to an animal or cell study of one component, or to a topical GHK-Cu skin study. None were tested for this blend.
• Topical evidence does not transfer to injections. The skin studies of GHK-Cu used creams. A cream and an injected blend are different products with different exposure.
• “Before and after” posts are not evidence. Photos and stories lack controls, blinding and objective measures. Lighting, angle, weight change, other products and ordinary healing all confound them. Someone who looks or feels better after starting something has not shown that the something caused it.
• What would count as evidence? A randomized, placebo-controlled trial with pre-specified, objective outcomes and reported adverse events. For a “glow” skin claim, that means blinded assessment of measurable skin outcomes. None exists for Glow.

Notably, several clinic pages that promote Glow acknowledge these limits themselves: one says human trials of the blend are virtually nonexistent (Midi Health), and another says much of the evidence is preclinical (Age Rejuvenation).

Glow vs Klow vs Wolverine vs single peptides

How to choose. If your protocol needs to attribute an effect to a single compound, use single-peptide vials, because a fixed-ratio blend cannot separate them. If it deliberately tests a combination in a set ratio, a blend reduces vial handling. For the four-peptide version, see our Klow peptide guide, which explains Glow peptide vs Klow in depth; for the two-peptide version, see the Wolverine peptide guide.

Glow → · Klow80 → · Wolverine → · GHK-Cu → · BPC-157 → · TB-500 →

Glow peptide dosage: why there is no established one

“Glow peptide dosage” gets about 6,600 searches a month, with “dosage chart” (2,900) and “Glow peptide protocol” (1,000) adding more. The direct answer is that there is no evidence-based dose for Glow, and this guide does not give one.

Here is why any chart you find online should not be treated as a dose:

1. No human trial has tested the blend. Doses on charts are borrowed from animal work, other products, vendor material or anecdote.
2. Each component lacks an established dose for this use. For BPC-157, USADA states it is unknown whether any dose is safe (USADA). The human thymosin beta-4 trials tested pharmaceutical products at trial-specific doses, which do not transfer to a research vial.
3. Even the sellers disagree. One clinic page we read states there is no consistent medical protocol for dosage or schedule, and another says amounts are set individually and not published. If clinics will not publish a number, a chart on a forum is not one either.
4. The ratio is fixed. Because GHK-Cu is 71% of the blend by mass, any amount of Glow delivers five times as much GHK-Cu, by mass, as each other peptide. You cannot adjust one without the others.
5. Concentration is not a dose. Concentration is a laboratory property of a solution. It says nothing about how much of anything is appropriate.

What lab users legitimately need is concentration math, which depends only on mass and volume:

Concentration (mg/mL) = peptide mass (mg) ÷ diluent volume (mL)

The same reasoning answers “Glow peptide injection” questions, including “how often do you inject Glow peptides?” There is no established schedule, because no controlled human trial has tested one, and Peptryn’s products are not for human injection or self-administration, so this guide gives no injection instructions.

Reconstitution and handling of Glow in the lab

For a 70 mg vial, the concentration of the whole blend and of each component depends on how much diluent is added:

This is arithmetic for laboratory concentration records, not a dosing table. Confirm the vial can hold the total volume you add.

Handling basics (per the Peptryn product specification and standard practice):

• Store the lyophilized powder at −20 °C, protected from light and repeated freeze-thaw cycles.
• Let the vial and diluent reach room temperature, disinfect the stoppers, and add bacteriostatic water slowly down the inner wall of the vial. Swirl gently, never shake.
• Refrigerate the reconstituted solution at 2-8 °C. Bacteriostatic water is usable for up to 28 days once opened, but we found no published stability data for a reconstituted three-peptide blend, so shorter is safer.
• GHK-Cu is a copper complex, and copper peptide solutions can carry a bluish tint. A clear solution with a slight tint is not necessarily a problem, but cloudiness, particles or strands are. If in doubt, discard it and contact support with your lot number.

For the full step-by-step process, see the reconstitution basics guide, the bacteriostatic water guide, the peptide calculator, and the storage and handling guide. Bacteriostatic water is available here: BAC Water 10 mL →

Glow peptide side effects and safety

No reliable side-effect profile exists for the blend, and this guide does not claim one. What can be said is organized by how much we know.

Known. The topical GHK-Cu literature describes decades of cosmetic use without reported adverse effects, but that applies to skin products, not injections. The three BPC-157 human reports (30 people in total) reported no adverse events. Some clinic pages describe injection-site redness or tenderness as the main local effect; those are descriptions from sellers, not trial data.

Theoretical. Reviewers of BPC-157 have raised the concern that a compound promoting blood-vessel growth could, in principle, support unwanted vessel growth. A 2026 review of unregulated injectable peptides lists contamination, manufacturing impurities, inaccurate dosing, pathological angiogenesis and carcinogenesis among the potential risks of unapproved peptides including BPC-157 and TB-500 (Moiz et al., 2026). These are proposed risks, not observed ones in a trial of Glow.

Unknown.

• Long-term safety of any component, alone or combined
• Any safe or effective dose in humans
• Interactions between the three peptides, and with other drugs
• Effects of the copper in GHK-Cu when combined with the others

Practical, present risk. The FDA points to aggregation and impurities as drivers of immune reactions for injectable peptides. Product quality can matter as much as the molecule, which is why batch-level testing of each component is the most useful thing a researcher can verify.

Regulatory and sport status

FDA. None of the three is an FDA-approved drug for these uses. Points to keep straight:

• GHK-Cu (injectable): listed on the FDA’s page of bulk drug substances that may present significant safety risks, for possible immunogenicity from aggregation and impurities, and limited human data (FDA).
• BPC-157 and TB-500: on July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to recommend adding BPC-157, KPV and TB-500 to the list of substances pharmacies may compound (each was nominated for a specific use, such as ulcerative colitis for BPC-157) (Pharmaceutical Executive). GHK-Cu was not among the peptides in the coverage we read.
• These votes are advisory. The FDA is not bound by them, and trade coverage reports a formal rulemaking of roughly eight to twelve months would have to follow before pharmacies could compound. They do not make any of these peptides approved drugs. Regulatory status changes, so verify the current position before relying on it.

Sport. BPC-157 is prohibited at all times under the S0 (non-approved substances) category of the WADA Prohibited List, and USADA states that it is unknown whether any dose is safe (USADA). TB-500, a thymosin beta-4 derivative, is addressed under the S2 class of the WADA Prohibited List. Because Glow contains both, athletes subject to testing should treat it as prohibited.

Sale as research material. Peptryn supplies peptides for laboratory research only, to buyers who are 21 or older and who confirm qualified research use. It is not a compounding pharmacy and does not offer these products for human use.

Glow peptide reviews and Reddit: how to read anecdotes

Searches for “Glow peptide review” and “Glow peptide Reddit” show people looking for other users’ experiences. A few points on reading them:

• Anecdotes are not trials. They can generate questions but cannot show that a product works or is safe.
• Watch the incentives. Many “reviews” come from sellers, affiliates or clinics with something to sell.
• Product reviews are not efficacy evidence. A review of shipping speed or packaging says nothing about biological effect.
• Verify, then trust. A vendor’s own documents (lot-specific COAs) are more useful than any testimonial.

This guide contains no testimonials, because they would not be evidence. What you can check for yourself are batch certificates in the COA library, including the Glow COA.

How to evaluate a Glow vial before you buy

Because “Glow” is a name and not a standard, the paperwork is what separates a reliable vial from a mislabeled one. Use this checklist.

1. A COA for your specific lot. It should show the lot number and date, not a generic sample. The Glow COA on file lists batch 2026-07-07, tested by MZ Biolabs by HPLC-UV-MS.
2. Identity for each of the three peptides by mass spectrometry. A blend needs three identities confirmed, not one.
3. Per-component purity. Look for ≥99% for each peptide, not just a combined figure. A single “blend purity” number can hide a wrong ratio, so if a summary shows only one figure, ask whether per-component data are in the full report.
4. The GHK-Cu mass. A listing that quotes 340.38 Da is quoting the peptide without copper; the copper complex is about 401-403 Da. Ask what species the lab actually confirmed, and treat a listing whose formula and weight do not match as a red flag.
5. The TB-500 form. Ask whether it is the 7-amino-acid fragment or full-length thymosin beta-4. The evidence, and the mass, differ.
6. Endotoxin testing. Relevant for any material handled in solution.
7. An independent lab. Peptryn’s batch testing is done by MZ Biolabs, with certificates published by lot.
8. A clear statement of composition and amounts. You should know the milligrams of each peptide per vial.
9. No medical claims from the seller. A supplier promising results for a research chemical is signaling the wrong thing.
10. Correct storage and shipping. Lyophilized powder should be stored cold and protected from light.

Not sure how to read the paperwork? Peptryn’s guide on how to read a certificate of analysis walks through each line. If a lot’s COA isn’t published yet, email support with your order number and they will send the current report on file.

Orders ship from the USA with same-day dispatch, and orders over $150 ship free. Volume discounts of 3%, 5% and 10% apply at 3, 5 and 10 units.

Get Glow with a batch COA →

---

Frequently asked questions

What is Glow peptide?

Glow is a research blend of three peptides, GHK-Cu, BPC-157 and TB-500, most often sold as a 70 mg vial (50 / 10 / 10 mg). It is a market name rather than a standardized product, so amounts and even the form of TB-500 can differ by seller.

What is in Glow peptide?

Peptryn’s Glow contains GHK-Cu (50 mg), BPC-157 (10 mg) and TB-500 (10 mg, listed as thymosin beta-4 acetate) in a 70 mg vial. Check the COA for your lot.

Does Glow peptide work?

No controlled human trial has tested the blend, so there is no evidence that it does. Cell and animal studies of the individual components report effects on tissue repair, and topical GHK-Cu has small human skin studies, but none of that was tested for this blend.

What are the Glow peptide side effects?

No reliable profile exists for the blend. The FDA has raised immunogenicity and impurity concerns about injectable GHK-Cu and has identified no human exposure data for the TB-500 fragment. See the safety section above.

Is Glow peptide safe?

Safety has not been established. Human data for the components are limited, mostly topical or very small, or come from pharmaceutical products that are not the same as a research vial.

How often do you inject Glow peptides?

There is no established schedule, because no controlled human trial has tested one. Peptryn’s products are for laboratory research only and are not for human injection or self-administration, so this guide gives no injection instructions.

What is the difference between NAD+ and Glow?

They are unrelated compounds. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in cells, not a peptide. Glow is a three-peptide blend. Peptryn lists NAD+ as a separate product.

Does Glow peptide help with fat loss?

No evidence shows that it does. None of GHK-Cu, BPC-157 or TB-500 is a GLP-1 drug; the fat-loss reputation of some peptides comes from a different class, such as semaglutide, tirzepatide and retatrutide.

What is the difference between Glow and Klow?

Klow is Glow plus KPV. Peptryn’s Glow is 70 mg (GHK-Cu 50, BPC-157 10, TB-500 10 mg), and Klow80 adds 10 mg of KPV for 80 mg. See our Klow peptide guide.

Is Glow peptide FDA-approved?

No. None of GHK-Cu, BPC-157 or TB-500 is an approved drug for these uses, and a July 2026 advisory committee vote on BPC-157 and TB-500 was not an approval.

Is Glow peptide legal?

It is sold in the US as a research chemical for laboratory use. It is not approved for human use, and BPC-157 and TB-500 are banned in tested sports. If you have a legal question about your situation, consult an attorney.

How much does Glow peptide cost?

The Glow peptide price at Peptryn is $150 per 70 mg vial, with volume discounts from three vials. Any “per month” figure would depend on a usage protocol, and no human protocol has been established.

Glow peptides for sale: where can researchers buy them?

Peptryn supplies Glow in 70 mg vials with batch-specific certificates of analysis. View the product → Buyers must be 21 or older and confirm laboratory research use.

---

Final take

The Glow peptide is best understood as a marketing name for a hypothesis: that GHK-Cu, BPC-157 and thymosin beta-4 might support tissue repair through complementary mechanisms. The laboratory research behind each component is genuine, and there are real human trials underway for some of them. But the trials test one product, one route and one purpose at a time, none tests the three together, and none tests a research vial. Anyone selling a Glow dose, a Glow schedule or a promised result is going further than the evidence allows.

For researchers, that makes documentation the useful part: a lot-specific COA, identity confirmed for each peptide, the TB-500 form stated, and the GHK-Cu mass that matches its formula.

See Glow with its batch COA → · Browse research blends →

Related guides: BPC-157 research guide · Klow peptide guide · Wolverine peptide guide · How to read a certificate of analysis · Reconstitution basics for laboratory peptides · Proper storage and handling of research peptides · Peptide calculator · What is a COA? · Peptide purity · Peptide testing · Popular peptides

---

Editorial note: Peptryn sells the research peptides discussed in this guide for laboratory use only. This guide is informational and is not medical advice. Sources are listed below. To report an error, email [email protected].

Sources

• Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci, 2018. pmc.ncbi.nlm.nih.gov
• McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med, 2025. pmc.ncbi.nlm.nih.gov
• Moiz A, O’Keefe EL, O’Keefe JH. Dangers of Injectable Peptides and Other Unregulated “Biohacking” Drugs. Missouri Medicine, 2026. pmc.ncbi.nlm.nih.gov
• ClinicalTrials.gov: NCT07437586 (topical GHK-Cu gel), NCT07437547 and NCT07803250 and NCT02637284 (BPC-157), NCT00832091, NCT03937882, NCT04555824 and NCT05984134 (thymosin beta-4), NCT07487363 (TB-500 fragment). Registry data as of September 2026.
• U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. fda.gov
• Pharmaceutical Executive. FDA Panel Votes to Loosen Restrictions for Four Peptides, July 24, 2026. pharmexec.com
• U.S. Anti-Doping Agency. BPC-157 peptide: prohibited. usada.org and the WADA Prohibited List
• PubChem, National Library of Medicine: glycyl-L-histidyl-L-lysine (CID 73587) and copper tripeptide entries, for peptide and copper-complex molecular weights.
• Clinic pages reviewed for how “Glow” is described: Midi Health, Age Rejuvenation, Plastic Surgery Key

---

All products on peptryn.com are intended for laboratory research purposes only. Not for human consumption, self-administration, or veterinary use. The information on this page has not been evaluated by the U.S. Food and Drug Administration and is not intended to diagnose, treat, cure, or prevent any disease. Nothing here should be construed as medical advice.